CN Patent

CN117562905A — 化疗方案期间免疫反应的保持

Assigned to Hainan Xiansheng Zaiming Pharmaceutical Co ltd · Expires 2024-02-20 · 2y expired

What this patent protects

以非常特定的剂量方案添加选择性的、快速起效的短半衰期CDK 4/6抑制剂到化疗与检查点抑制剂的组合中在肿瘤或癌症的治疗中提供了优异的结果。意外的发现是，在三联疗法的化疗部分施用期间短时间脉冲的选择性的、快速起效的短半衰期CDK 4/6抑制剂的特定定时施用对癌症微环境中的免疫细胞具有深远的影响。

USPTO Abstract

以非常特定的剂量方案添加选择性的、快速起效的短半衰期CDK 4/6抑制剂到化疗与检查点抑制剂的组合中在肿瘤或癌症的治疗中提供了优异的结果。意外的发现是，在三联疗法的化疗部分施用期间短时间脉冲的选择性的、快速起效的短半衰期CDK 4/6抑制剂的特定定时施用对癌症微环境中的免疫细胞具有深远的影响。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN117562905A
Jurisdiction: CN
Classification: —
Expires: 2024-02-20
Drug substance claim: No
Drug product claim: No
Assignee: Hainan Xiansheng Zaiming Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.